Exploring social harms during distribution of HIV self-testing kits using mixed-methods approaches in Malawi.
Adolescent
Adult
Data Collection
Female
Focus Groups
HIV Infections
/ epidemiology
HIV Seropositivity
/ diagnosis
Humans
Malawi
/ epidemiology
Male
Mass Screening
/ methods
Reagent Kits, Diagnostic
Serologic Tests
/ economics
Sexual Partners
Spouses
Surveys and Questionnaires
Truth Disclosure
Young Adult
HIV self-test
HIV testing
HIV/AIDS
Malawi
social harms
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
10
05
2018
accepted:
24
01
2019
entrez:
26
3
2019
pubmed:
26
3
2019
medline:
16
7
2020
Statut:
ppublish
Résumé
HIV self-testing (HIVST) provides couples and individuals with a discreet, convenient and empowering testing option. As with all HIV testing, potential harms must be anticipated and mitigated to optimize individual and public health benefits. Here, we describe social harms (SHs) reported during HIVST implementation in Malawi, and propose a framework for grading and responding to harms, according to their severity. We report findings from six HIVST implementation studies in Malawi (2011 to 2017) that included substudies investigating SH reports. Qualitative methods included focus group discussions, in-depth interviews and critical incident interviews. Earlier studies used intensive quantitative methods (post-test questionnaires for intimate partner violence, household surveys, investigation of all deaths in HIVST communities). Later studies used post-marketing reporting with/without community engagement. Pharmacovigilance methodology (whereby potentially life-threatening/changing events are defined as "serious") was used to grade SH severity, assuming more complete passive reporting for serious events. During distribution of 175,683 HIVST kits, predominantly under passive SH reporting, 25 serious SHs were reported from 19 (0.011%) self-testers, including 15 partners in eight couples with newly identified HIV discordancy, and one perinatally infected adolescent. There were no deaths or suicides. Marriage break-up was the most commonly reported serious SH (sixteen individuals; eight couples), particularly among serodiscordant couples. Among new concordant HIV-positive couples, blame and frustration was common but rarely (one episode) led to serious SHs. Among concordant HIV-negative couples, increased trust and stronger relationships were reported. Coercion to test or disclose was generally considered "well-intentioned" within established couples. Women felt empowered and were assertive when offering HIVST test kits to their partners. Some women who persuaded their partner to test, however, did report SHs, including verbal or physical abuse and economic hardship. After more than six years of large-scale HIVST implementation and in-depth investigation of SHs in Malawi, we identified approximately one serious reported SH per 10,000 HIVST kits distributed, predominantly break-up of married serodiscordant couples. Both "active" and "passive" reporting systems identified serious SH events, although with more complete capture by "active" systems. As HIVST is scaled-up, efforts to support and further optimize community-led SH monitoring should be prioritized alongside HIVST distribution.
Identifiants
pubmed: 30907508
doi: 10.1002/jia2.25251
pmc: PMC6432111
doi:
Substances chimiques
Reagent Kits, Diagnostic
0
Banques de données
ISRCTN
['ISRCTN02004005', 'ISRCTN18421340']
ClinicalTrials.gov
['NCT02718274']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25251Subventions
Organisme : Wellcome Trust
ID : 105828/Z/14/Z
Pays : United Kingdom
Organisme : Unitaid
Pays : International
Organisme : Wellcome Trust
ID : 200901/Z/16/Z
Pays : United Kingdom
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Wellcome Trust
ID : WT200901
Pays : United Kingdom
Informations de copyright
© 2019 World Health Organization; licensed by IAS.
Références
Lancet. 2013 May 4;381(9877):1519-21
pubmed: 23391463
AIDS. 2017 Jul 1;31 Suppl 3:S203-S212
pubmed: 28665878
AIDS Behav. 2014 Jul;18 Suppl 4:S445-9
pubmed: 24989129
Curr Opin Infect Dis. 2018 Feb;31(1):14-24
pubmed: 29232277
PLoS Med. 2012;9(10):e1001329
pubmed: 23109914
J Int AIDS Soc. 2018 Mar;21(3):e25098
pubmed: 29577598
PLoS Med. 2015 Sep 08;12(9):e1001873
pubmed: 26348035
PLoS Med. 2016 Nov 8;13(11):e1002166
pubmed: 27824882
J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):e22-e25
pubmed: 29112043
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25244
pubmed: 30907505
PLoS Med. 2019 Jan 2;16(1):e1002719
pubmed: 30601823
AIDS Behav. 2014 Jul;18 Suppl 4:S396-404
pubmed: 24929834
Soc Work Health Care. 2000;31(4):25-41
pubmed: 11140341
AIDS Behav. 2014 Jan;18(1):189-93
pubmed: 23728523
AIDS. 2011 Oct 23;25(16):2009-18
pubmed: 21811146
Trials. 2017 Jul 24;18(1):349
pubmed: 28738857
Lancet. 2013 May 4;381(9877):1561-9
pubmed: 23391466
J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):467-473
pubmed: 30148731
AIDS Care. 1998 Oct;10(5):533-48
pubmed: 9828951
Lancet Infect Dis. 2012 Jul;12(7):538-49
pubmed: 22424777
BMC Public Health. 2018 Nov 6;18(1):1234
pubmed: 30400959
Drug Saf. 2006;29(5):385-96
pubmed: 16689555
Bull World Health Organ. 2012 Sep 1;90(9):652-658B
pubmed: 22984309
JAMA. 2014 Jul 23-30;312(4):372-9
pubmed: 25038356
J Int AIDS Soc. 2015 Dec 01;18(Suppl 5):20292
pubmed: 26643462
Bull World Health Organ. 2004 Apr;82(4):299-307
pubmed: 15259260
J Int AIDS Soc. 2017 May 15;20(1):21594
pubmed: 28530049
BMC Public Health. 2018 Jun 28;18(1):807
pubmed: 29954360
Lancet HIV. 2016 Jun;3(6):e266-74
pubmed: 27240789
J Int AIDS Soc. 2016 Mar 31;19(1):20766
pubmed: 27037140
PLoS Med. 2017 Nov 28;14(11):e1002458
pubmed: 29182634
AIDS Care. 2016;28 Suppl 3:59-66
pubmed: 27421052
AIDS Behav. 2018 Aug;22(8):2491-2499
pubmed: 29411227
BMJ. 2010 Sep 17;341:c4587
pubmed: 20851841
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25251
pubmed: 30907508
PLoS Med. 2017 Nov 21;14(11):e1002442
pubmed: 29161260
J Int AIDS Soc. 2017 Jun 26;20(1):21610
pubmed: 28691442